

Product Specification Sheet

Malondialdehyde (MDA) Antibodies and MDA Conjugate

Cat # MDA11-S
Cat # MDA35-N-100

Rabbit Anti-MDA antiserum # 1
Malondialdehyde (MDA)-BSA Conjugate positive control for Western/ELISA

SIZE: 100 ul
SIZE: 100 ug

MDA (Malondialdehyde) is a highly reactive three carbon dialdehyde produced as a byproduct of polyunsaturated fatty acid peroxidation and arachidonic acid metabolism. MDA readily combines with several functional groups on molecules including proteins, lipoproteins, and DNA. MDA-modified proteins may show altered physico-chemical behavior and antigenicity. Antibodies to MDA will help to visualize the MDA-adducts.

Source of Antigen, Antibodies, and controls

#MDA11-S

Antigen	MDA (ADI cat # MDA51-10) was coupled with KLH
Ab Host/type	Rabbit, Polyclonal antiserum # MDA11-S
2-Ab	Cat # 20320, goat anti-rabbit IgG-HRP (AP, biotin, FITC conjugates also available).
-ve control IgG	Cat # 20009-1, Rabbit (non-immune) Serum IgG, purified, suitable for ELISA, Western, IHC as -ve control

#MDA35-N-100 (MDA-BSA Conjugate)

MDA was coupled to bovine serum albumin (BSA) using proprietary methods. It is supplied in PBS, pH 7.4 at 100 ug/100 ul in liquid or lyophilized in the same buffer. **Reconstitute** powder in PBS at 1 mg/ml. Store frozen at -20oC in aliquots.

MDA-BSA conjugate is suitable for use in ELISA (coat at 1-10 ug/ml) and detect with appropriate antibodies (#MDA11-S). It may be used for western as a positive control but aggregates of BSA or polymers may also be seen upon long storage.

Form & Storage of Antibodies/Peptide Control

Antiserum (unpurified, undiluted)
100 ul/vial solution lyophilized powder
contains 0.05% sodium azide
Reconstitute powder in the original vol. of water

Storage

Short-term: unopened, undiluted vials for less than a week at 4oC.

Long-term: at -20C or below in suitable aliquots after reconstitution. Do not freeze and thaw and store working, diluted solutions.

Stability: 6-12 months at -20oC or below.
Shipping: 4oC for solutions and room temp for powder.

Recommended Usage

It is recommended that researchers test the antiserum, and controls and determine their own optimal condition. Anti-MDA antiserum may be diluted 1:500-1K or more **Western Blotting and histochemistry** and 1K-1:10K for **ELISA (See published refs at the web site)**

General References:

1. Yahya, ND et al (1996) J. Autoimmunity 9, 3-9;
2. Lung, CC et al (1992) Life Sci. 52, 329-337;
3. Lung et al (1990) J. Immunological Methods 128, 127-132;
4. Shah, G (1994) Life Sci. 55, 1343-1349

Citations of for ADI Antibodies (see updated list at the web site)

- Carrasco J, 2000, Eur. J. Neurosci. 12, 2311, , IHC,
Xu W, 2005, Spinal Cord, 43 p204-213,, , IHC
Powell CL, 2006, Toxicol. Sci. 93: 213 - 222, , IHC
Onozato LM, 2007, Nephrol. Dial. Transplant., 22: 1314 - 1322, , IHC
Hidalgo J, 2006, Exp Biol and Med, 231: 1450 - 1458., , IHC
Takaya T, 2005, Atherosclerosis 186, 402-410, , IHC
Espejo C, 2005, Neuroscience, 132, 245-248, , IHC,
Mazur-Kolecka B, 2003, Brain Res. 983, 48-57, , IHC,
Zhang M, 2007, Metabolism, 55, 1590-1598, , IHC
Liu N, 2005, Laboratory Investigation 85, 1471-1480, WB,
Grillo CA, 2003, Neuroscience, , in press
Penkowa M, 2005, Exp. Physiol. 90, 477-486, , IHC
Mazur-Kolecka B, 2005, NeuroBiol. Aging, 27, 804-814, , IHC,
Penkowa M, 2000, J. Cereb Blood Flow & Metabol. 20: 1174- IHC
Misawa H, 2006, Neurobiology of Disease, 23, 169-177, , IHC
Carrasco Javier, 2003, NeuroBiol. Disease 13, 22-36, , IHC,
Mazur-Kolecka B, 2005, Neurobiol Aging 27, 1181-1192, , IHC,
Penkowaa M, 2001, J Neuroimmunol 119, 248-260, , IHC,
Lin Y, 2006, J of Cerebl Blood Flow & Metab 27, 1010-1021, WB,
Khan MF, 2003, J Toxicol Environ Health A ;66:93-102, WB, IHC,
Penkowa M, 2003, Exp. Neurology 181, 130-148, , IHC/IF
Zhou H, 2006, Nephrol. Dial. Transplant 21, 616-623, WB, IHC
Penkowaa M, 2001, Neuroscience, 102, 805-818, , IHC,
Khan IA, 2004, Marine Environmental Res. 58, 333-336, WB?,

All products are for in vitro research use only.

Anti-MDA, Anti-HNE antibodies

MDA35-N-100

120424A